Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Biliary Tract Neoplasms 3Breast Neoplasms 2Uterine Neoplasms 1Sarcoma, Ewing 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1

Interventions

X-Rays 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 4ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2LY3023414 2talazoparib 1olaparib 1irinotecan sucrosofate 1amino-acid, glucose, and electrolyte solution 1Vemurafenib 1Temozolomide 1Pharmacogenomic Variants 1Liquid Biopsy 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive, Peripheral × Liquid Biopsy × 90 days × Clear all
NCT06068075 2026-05-05

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Dana-Farber Cancer Institute

Phase NA Active not recruiting
340 enrolled
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡